IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 51-75 out of 1279.

<< < 1 | 2 | 3 | 4 | 5 | 6 | 7 > >>

Public Release: 18-Nov-2014
Biophysical Journal
New computational model could design medications like chemotherapy with fewer side effects
Medications, such as chemotherapy, are often limited by their tendency to be detrimental to healthy cells as an unintended side effect. Now research in the Nov. 18 issue of Cell Press's Biophysical Journal offers a new computational model that can help investigators design ways to direct drugs to their specific targets.

Contact: Mary Beth O'Leary
moleary@cell.com
617-397-2802
Cell Press

Public Release: 18-Nov-2014
26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
First demonstration of anti-cancer activity for an IDH1 mutation inhibitor
A phase I trial of the first drug designed to inhibit the cancer-causing activity of a mutated enzyme known as isocitrate dehydrogenase (IDH) 1, which is involved in cell metabolism, has shown clinical activity in patients with advanced acute myeloid leukaemia with the IDH1 mutation. Professor Daniel Pollyea will tell the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics that early results from the phase 1 clinical trial of the drug AG-120 have been encouraging.
Agios Pharmaceuticals

Contact: Emma Mason
wordmason@mac.com
ECCO-the European CanCer Organisation

Public Release: 17-Nov-2014
Proceedings of the National Academy of Sciences
The dirty side of soap
Triclosan is an antimicrobial commonly found in soaps, shampoos, toothpastes and many other household items. Despite its widespread use, researchers at University of California, San Diego School of Medicine report potentially serious consequences of long-term exposure to the chemical.
US Public Health Service

Contact: Heather Buschman
hbuschman@ucsd.edu
619-543-6163
University of California - San Diego

Public Release: 17-Nov-2014
ecancermedicalscience
The secret life of anti-cancer drugs
The public is bombarded with news of exciting developments in cancer research every day, with new anti-cancer drugs greeted with excitement. In a new review published in ecancermedicalscience, researchers trace the journey anti-cancer drugs take between discovery and clinical practice.

Contact: Katie Foxall
katie@ecancer.org
01-179-420-852
ecancermedicalscience

Public Release: 17-Nov-2014
Nature Medicine
Potential therapy found for incurable pediatric brain tumor
scientists have discovered a new potential drug therapy for a rare, incurable pediatric brain tumor by targeting a genetic mutation found in children with the cancer. By inhibiting the tumor-forming consequences of the mutation using an experimental drug called GSKJ4, they delayed tumor growth and prolonged survival in mice with pediatric brainstem glioma.
National Institutes of Health

Contact: Marla Paul
marla-paul@northwestern.edu
312-503-8928
Northwestern University

Public Release: 17-Nov-2014
Nature
microRNA silencing provides a successful new model for cancer therapeutics
By exploiting a unique feature of the tumor microenvironment, scientists identify a novel delivery platform that leads to the inhibition of microRNA activity -- and the control of cancer growth.
National Institutes of Health

Contact: Bonnie Prescott
bprescot@bidmc.harvard.edu
617-667-7306
Beth Israel Deaconess Medical Center

Public Release: 17-Nov-2014
Nature Communications
A new approach to fighting chronic myeloid leukemia
Chronic myeloid leukemia is caused by the hyperactivity of a mutated enzyme. EPFL scientists have discovered an indirect way to regulate this enzyme that could prove more effective than current therapies.
ISREC Foundation, Swiss Cancer League

Contact: Nik Papageorgiou
n.papageorgiou@epfl.ch
41-216-932-105
Ecole Polytechnique Fédérale de Lausanne

Public Release: 17-Nov-2014
Annals of Internal Medicine
News from Nov. 18 Annals of Internal Medicine Supplement
The supplement is comprised of research conducted by current and former Robert Wood Johnson Foundation Clinical Scholars. The articles share a common theme of evaluating practical interventions for common clinical problems.

Contact: Megan Hanks
mhanks@acponline.org
215-351-2656
American College of Physicians

Public Release: 17-Nov-2014
Nature Genetics
UTSW cancer researchers identify gene mutations and process for how kidney tumors develop
Using next generation gene sequencing techniques, cancer researchers at University of Texas Southwestern Medical Center have identified more than 3,000 new mutations involved in certain kidney cancers, findings that help explain the diversity of cancer behaviors.
Genentech Inc.

Contact: Lori Sundeen Soderbergh
lori.soderbergh@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center

Public Release: 17-Nov-2014
Proceedings of the National Academy of Sciences
Anti-leukemia drug may also work against ovarian cancer
An antibody therapy already in clinical trials to treat chronic lymphocytic leukemia may also prove effective against ovarian cancer -- and likely other cancers as well, report researchers at the University of California, San Diego School of Medicine.
National Institutes of Health, California Institute for Regenerative Medicine, Blood Cancer Research Fund, UCSD Foundation and Cancer Center Support Grant

Contact: Scott LaFee
slafee@ucsd.edu
619-543-6163
University of California - San Diego

Public Release: 17-Nov-2014
Annals of Internal Medicine
Need to encourage patients to screen for colon cancer? Try a lottery
Convincing patients to do an often dreaded colon cancer screening test could just take a little extra nudge -- like a chance to win $50.
VA Center for Health Equity Research and Promotion, Robert Wood Johnson Foundation

Contact: Beata Mostafavi
bmostafa@umich.edu
734-764-2220
University of Michigan Health System

Public Release: 17-Nov-2014
Journal of Clinical Investigation
A noncoding RNA promotes pediatric bone cancer
Ewing sarcoma is a cancer of bone or its surrounding soft tissue that primarily affects children and young adults. A new study in the Journal of Clinical Investigation indicates that a long non-coding RNA named Ewing sarcoma-associated transcript 1 contributes to the complex network of changes that occur in Ewing Sarcoma.
Doris Duke Clinical Scientist Development Fund, St. Baldrick's Foundation, Kavner Family Fund, Hope Street Kids Foundation, Sunbeam Foundation, Elsa U. Pardee Foundation, Bear Necessities Foundation, Hyundai Hope on Wheels

Contact: Corinne Williams
press_releases@the-jci.org
919-684-0620
Journal of Clinical Investigation

Public Release: 17-Nov-2014
Lancet Oncology
Investigational oral drug combo shows promise for newly diagnosed multiple myeloma
The investigational drug ixazomib taken orally in combination with lenalidomide and dexamethasone shows promise in patients with newly diagnosed multiple myeloma, according to the results of a phase 1/2 study published in the journal Lancet Oncology.
Millennium Pharmaceuticals

Contact: Joe Dangor
newsbureau@mayo.edu
507-284-5005
Mayo Clinic

Public Release: 17-Nov-2014
Journal of Thoracic Oncology
Race, hospital, insurance status all factors in how lung cancer is treated
African Americans, Hispanics, and those who receive care at a community hospital are all significantly less likely than other patients to receive treatment for early stage non-small cell lung cancer, according to a report in the Journal of Thoracic Oncology.

Contact: Sharon Parmet
sparmet@uic.edu
312-413-2695
University of Illinois at Chicago

Public Release: 17-Nov-2014
Environmental Science & Technology
'Probiotics' for plants boost detox abilities; untreated plants overdose and die
Scientists using a microbe that occurs naturally in eastern cottonwood trees have boosted the ability of two other plants -- willow and lawn grass -- to withstand the withering effects of the nasty industrial pollutant phenanthrene and take up 25 to 40 percent more of the pollutant than untreated plants.
NIH/National Institute of Environmental Health Sciences, Byron and Alice Lockwood Endowed Professorship

Contact: Sandra Hines
shines@uw.edu
206-543-2580
University of Washington

Public Release: 17-Nov-2014
American Journal of Public Health
UTHealth smoking study: Financial incentives double quit rates
Offering small financial incentives doubles smoking cessation rates among socioeconomically disadvantaged smokers, according to research from the University of Texas Health Science Center at Houston.
American Cancer Society, University of Texas Health Science Center at Houston

Contact: Hannah Rhodes
Hannah.C.Rasorrhodes@uth.tmc.edu
713-500-3053
University of Texas Health Science Center at Houston

Public Release: 17-Nov-2014
Mayo Clinic Proceedings
Mayo Clinic researchers: TNF inhibitors may increase cancer risk in the eye
One of the family of drugs prescribed for rheumatoid arthritis and other inflammatory conditions is called tumor necrosis factor inhibitors. They act by dampening part of the immune system called tumor necrosis factor. In one of the balancing acts of medicine, the anti-inflammatory action of the drug also increases the risk for other conditions, in this case, a rare form of eye cancer, uveal melanoma. Mayo Clinic researchers make the case and alert physicians in an article in Mayo Clinic Proceedings
Terrance and Judi Paul, Research to Prevent Blindness, Inc

Contact: Robert Nellis
newsbureau@mayo.edu
507-284-5005
Mayo Clinic

Public Release: 17-Nov-2014
Proceedings of the National Academy of Sciences
First genetic-based tool to detect circulating cancer cells in blood
Northwestern University scientists have demonstrated the first genetic-based approach that is able to detect live circulating tumor cells out of the complex matrix that is human blood -- no easy feat. The NanoFlare technology potentially could detect cancer cells long before they could settle somewhere in the body and form a dangerous tumor. In a breast cancer study, the NanoFlares easily entered cells and lit up the cell if a biomarker target was present, even if only a trace amount.
NIH/National Cancer Institute, National Institutes of Health, American Cancer Society, Air Force Office of Scientific Research, Howard Hughes Medical Institute

Contact: Megan Fellman
fellman@northwestern.edu
847-491-3115
Northwestern University

Public Release: 17-Nov-2014
Cell Reports
Side effects of possible anti-cancer strategy discovered
The Malt1 protein is one of the most important control centers in human immune cells and a real all-rounder. Genetic defects in it can lead to the development of lymphatic cancer (lymphoma). A possible therapeutic approach is therefore to specifically block certain functions of Malt1, thus destroying the cancer cells. Now, however, scientists at Technische Universität München have shown in a mouse model that such a blockade can cause serious side effects.

Contact: Vera Siegler
vera.siegler@tum.de
49-892-892-2731
Technische Universitaet Muenchen

Public Release: 17-Nov-2014
Nature
Metabolic 'reprogramming' by the p53 gene family leads to tumor regression
Scientists have found that altering members of the p53 gene family, known as tumor suppressor genes, causes rapid regression of tumors that are deficient in or totally missing p53.

Contact: Ron Gilmore
rlgilmore1@mdanderson.org
713-745-1898
University of Texas M. D. Anderson Cancer Center

Public Release: 16-Nov-2014
Neuroscience 2014
'Not just a flavoring:' Menthol and nicotine, combined, desensitize airway receptors
This study suggests menthol doesn't just act as a flavoring, but has a pharmacologic impact. The researchers say menthol acts in combination with nicotine to desensitize receptors in lungs' airways that are responsible for nicotine's irritation. Though not a focus of the work, the findings are important as FDA is considering restrictions on menthol cigarettes.
National Institutes of Health

Contact: Karen Teber
km463@georgetown.edu
215-514-9751
Georgetown University Medical Center

Public Release: 16-Nov-2014
Neuroscience 2014
Molecular Neurodegeneration
Tau, not amyloid-beta, triggers neuronal death process in Alzheimer's
New research points to malfunctioning tau, not amyloid-beta (Abeta) plaque, as the seminal event that spurs neuron death in disorders such as Alzheimer's disease. The lead Georgetown neuroscientist investigating the work explains the finding and the potential of an already approved drug in mediating the problem at the annual meeting of the Society for Neuroscience, Tuesday, Nov. 18, 8:15 a.m. in room WCC152A.
Georgetown University, Merck & Co.

Contact: Karen Teber
km463@georgetown.edu
Georgetown University Medical Center

Public Release: 15-Nov-2014
Society for Neuro-Oncology's 19th Annual Meeting
Chemotherapy following radiation treatment slows disease progress
A chemotherapy regimen consisting of procarbazine, CCNU, and vincristine administered following radiation therapy improved progression-free survival and overall survival in adults with low-grade gliomas, a form of brain cancer, when compared to radiation therapy alone. The findings were part of the results of a Phase III clinical trial presented today at the Society for Neuro-Oncology's 19th Annual Meeting in Miami by the study's primary author Jan Buckner, M.D., deputy director, practice, at Mayo Clinic Cancer Center.
NIH/National Cancer Institute, Radiation Treatment Oncology Group, Alliance for Clinical Trials in Oncology, Eastern Cooperative Oncology Group, Southwest Oncology Group

Contact: Jan Dangor
newsbureau@mayo.edu
507-284-5005
Mayo Clinic

Public Release: 14-Nov-2014
Nature Scientific Reports
Cutting-edge computer software helps pinpoint aggressiveness of breast cancer tumors
Researchers at Western University are using cutting-edge genetic mutation-analysis software developed in their lab to interpret mutations in tumor genome that may provide insight into determining which breast cancer tumors are more likely spread to other parts of the body and which ones won't.

Contact: Crystal Mackay
crystal.mackay@schulich.uwo.ca
519-661-2111 x80387
University of Western Ontario

Public Release: 14-Nov-2014
Cancer Research
New imaging technique identifies receptors for targeted cancer therapy
Dartmouth researchers have developed a fluorescence imaging technique that can more accurately identify receptors for targeted cancer therapies without a tissue biopsy. They report on their findings in 'Quantitative in vivo immunohistochemistry of epidermal growth factor receptor using a receptor concentration imaging approach,' which was recently published in Cancer Research.
National Institutes of Health

Contact: Robin Dutcher
Robin.Dutcher@hitchcock.org
603-653-9056
The Geisel School of Medicine at Dartmouth

Showing releases 51-75 out of 1279.

<< < 1 | 2 | 3 | 4 | 5 | 6 | 7 > >>

  Search News Releases

     

 

EurekAlert!